Patents Assigned to Takeda Pharmaceutical Company Limited
  • Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
    Patent number: 11661593
    Abstract: Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: May 30, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Meinhard Hasslacher, Christian Fiedler, Christa Mayer, Artur Mitterer
  • T CELL PROGENITOR PRODUCTION METHOD
    Publication number: 20230159891
    Abstract: The following are disclosed: a method for producing a T cell progenitor, including step (1) of culturing CD34+ cell in a medium containing an aryl hydrocarbon receptor antagonist, a medium for T cell progenitor differentiation containing an aryl hydrocarbon receptor antagonist, and a T cell progenitor inducer containing an aryl hydrocarbon receptor antagonist.
    Type: Application
    Filed: March 30, 2021
    Publication date: May 25, 2023
    Applicants: Kyoto University, TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Shin KANEKO, Shoichi IRIGUCHI
  • Alginate hydrogel compositions
    Patent number: 11655343
    Abstract: The present application provides a semi-permeable hydrogel composition comprising an alginate matrix that is covalently crosslinked in its periphery to a multi-armed water soluble polymer, along with related methods and uses thereof.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: May 23, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Venkata R. Garigapati, Tetsuo Hoshino, Amit Garle
  • Heterocyclic compound and use thereof
    Patent number: 11655241
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: May 23, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tsuneo Oda, Yoshiteru Ito, Tohru Miyazaki, Kohei Takeuchi, Norihito Tokunaga, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura, Yuichi Kajita, Yuhei Miyanohana, Takahiro Sugimoto, Tatsuki Koike, Dilhumar Uyghur
  • ORAL SOLID PREPARATIONS
    Publication number: 20230149396
    Abstract: Disclosed herein are oral solid preparations comprising a D-amino acid oxidase (DA AO) inhibitor, a low-substituted hydroxypropyl cellulose (L-HPC), and an additive, wherein the DAAO inhibitor is a pyridazinone derivative, methods for producing the same, and methods of using the same m the prevention or treatment of diseases preventable or treatable using DAAO inhibitors.
    Type: Application
    Filed: March 3, 2021
    Publication date: May 18, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tetsuya SUEHARA, Miyuki HOHOKABE, Kazuki HARADA
  • Method of predicting a performance characteristic of a plant or yeast hydrolysate and its use
    Patent number: 11650159
    Abstract: The present invention relates to a method of predicting a performance characteristic of a plant or yeast hydrolysate, wherein a plant or yeast hydrolysate sample is measured with 2D fluorescence spectroscopy in powder form. Said method comprises the steps for providing a model based on a predetermined value of a manufacturing parameter of interest. For this purpose a training set consisting of predetermined manufacturing parameter of interest (e.g volumetric productivity parameter, virus titer or cell number) and fluorescence spectroscopic data is used. The fluorescence spectroscopic data is correlated to the values of the manufacturing parameter of interest to obtain a calibration model/model parameters by applying multivariate data analysis. This calibration model is being used to predict the manufacturing parameter of interest for new samples dedicated for the manufacturing process.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: May 16, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Renata Baldaszti-Juric, Leopold Grillberger, Wolfgang Langer, Manfred Reiter
  • Method for producing pyrrole compound
    Patent number: 11649206
    Abstract: The present invention provides a production method of a 3-cyanopyrrole compound possibly useful as an intermediate for pharmaceutical products. A production method of compound (II) including subjecting compound (I) to a reduction reaction, in which the aforementioned reduction reaction is continuous hydrogenation reaction in a fixed bed reactor filled with a supported metal catalyst. A production method of compound (III) including subjecting compound (I) to a reduction reaction followed by a cyclization reaction, in which the aforementioned reduction reaction is continuous hydrogenation reaction in a fixed bed reactor filled with a supported metal catalyst.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: May 16, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takashi Ouchi, Giho Goh, Sunmi Kim, Jinsoon Choi, Hunsoo Park
  • Subcutaneous Port With Locking Member
    Publication number: 20230143477
    Abstract: A subcutaneous port assembly includes a base, a connector, a stem, a sealing element, and a locking member. The connector extends from a first end attached to the base to a distal end and includes an inner surface defining a socket having an inside diameter. The stem extends from the base and into the socket. The stem includes an outer surface having an outside diameter that is less than the inside diameter of the socket. The sealing element is disposed within the socket between the stem and the inner surface of the socket. The locking member has a plunger received within the socket from the distal end and having a terminal end facing the sealing element. The plunger is axially movable between a first position and a second position to selectively compress the sealing element within the socket.
    Type: Application
    Filed: April 2, 2021
    Publication date: May 11, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Ayesha Arzumand, Chris Tarapata, Marc Bellisario, Christel Hartshorn, Matthew J. Gunn, Chase Fetzer
  • NON-ADULT HUMAN DOSING OF ANTI-CD30 ANTIBODY-DRUG CONJUGATES
    Publication number: 20230136346
    Abstract: The invention provides, inter alia, methods of treating a disorder characterized by pathological activity of CD30+ cells, such as in certain solid, hematological and lymphoid cancers, in a non-adult human subject by administering an effective amount of an anti-CD30 ADC (antibody drug conjugate), such as, brentuximab vedotin, to the subject. The invention also provides corresponding kits and articles of manufacture suitable for performing the methods provided by the invention.
    Type: Application
    Filed: September 2, 2022
    Publication date: May 4, 2023
    Applicant: Takeda Pharmaceutical Company Limited.
    Inventor: Adedigbo Fasanmade
  • NOVEL ACTIVITY-BASED PROBES FOR NEUTROPHIL ELASTASE AND THEIR USE
    Publication number: 20230140838
    Abstract: The present invention relates to compounds of formula I, wherein D is a detectable moiety, or salts thereof, which can be used as activity-based probes for neutrophil elastase, as well as to methods for detecting neutrophil elastase (NE) activity in a tissue sample lysate, and related diagnostic methods using compounds of formula I.
    Type: Application
    Filed: December 20, 2019
    Publication date: May 4, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Laura EDGINGTON-MITCHELL, Bethany M. ANDERSON, Daniel P. POOLE, Luigi AURELIO, Paulina KASPERKIEWICZ, Marcin DRAG, Nigel BUNNETT
  • MEDICINAL FLUID DELIVERY DEVICE
    Publication number: 20230140678
    Abstract: In some embodiments, a reconstitution or medicinal fluid delivery device includes a transfer engine including two fluidly connected spikes, each configured to pierce a container. A check valve may be disposed between the two spikes to allow unidirectional flow from one container to the other. Physical access to a fluid outlet may be obstructed by a housing until the reconstitution or medicinal fluid delivery device is actuated, whereupon physical access to the fluid outlet is permitted. The reconstitution or medicinal fluid delivery device may be placed on a flat surface and actuated with force applied in a single direction toward the flat surface.
    Type: Application
    Filed: March 5, 2021
    Publication date: May 4, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Joseph M. Giamo, Thomas Boyajian, Amey Mathakari, Anh Nguyen, Dhairya Kiritkumar Mehta
  • BISPECIFIC ANTIBODIES AGAINST PLASMA KALLIKREIN AND FACTOR XII
    Publication number: 20230117565
    Abstract: Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis.
    Type: Application
    Filed: June 13, 2022
    Publication date: April 20, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Stephen R. Comeau, Andrew Nixon, Niksa Kastrapeli, Jon A. Kenniston, Gregory P. Conley, Shauna Mason, Allison P. Lindberg, Kristopher Kopacz, Burt Adelman
  • NITROGEN CONTAINING HETEROCYCLES AS CDK12 INHIBITORS
    Publication number: 20230117295
    Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: December 6, 2022
    Publication date: April 20, 2023
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Koji ONO, Masahiro ITO, Toshio TANAKA, Moriteru ASANO, Takaharu HIRAYAMA, Jun FUJIMOTO, Nobuki SAKAUCHI, Yasuhiro HIRATA, Akinori TOITA, Nao MORISHITA, Hironori KOKUBO, Yasuhiro IMAEDA, Hironobu MAEZAKI, Douglas Robert CARY, Ryo MIZOJIRI, Nobuo CHO, Hiroshi BANNO, Hidekazu TOKUHARA, Yasuyoshi ARIKAWA
  • ISOFAGOMINE SALTS, METHODS OF USE AND FORMULATIONS
    Publication number: 20230110129
    Abstract: The present invention relates generally to the field of pharmaceuticals, and specifically relates to isofagomine (IFG), novel salts thereof and preparation methods and uses of these, for example, in formulating pharmaceutical compositions for the treatment of Gaucher disease. Also provided are novel crystalline forms of isofagomine salts, methods for preparing the crystalline forms, and their use in formulating pharmaceutical compositions.
    Type: Application
    Filed: April 24, 2020
    Publication date: April 13, 2023
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Helge REISCH, Jeffrey Scott DEPUE, Fritz BLATTER, Jennifer ROBIN, Michael Peter HAHN, Gaozhong ZHU, Muthuraman MEIYAPPAN
  • PLASMA KALLIKREIN BINDING PROTEINS
    Publication number: 20230112931
    Abstract: Plasma kallikrein binding proteins and methods of using such proteins are described.
    Type: Application
    Filed: June 17, 2022
    Publication date: April 13, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Malini Viswanathan
  • PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING HEREDITARY ANGIOEDEMA ATTACK
    Publication number: 20230104754
    Abstract: Provided herein are methods of treating and preventing hereditary angioedema attack in certain human patient subpopulations using antibodies binding to active plasma kallikrein with specific treatment regimens, for example, at about 300 mg every two weeks. Exemplary human patient subpopulations include female patients, patients less than 18 years old, between 40 and less than 65 years old, adolescent patients, patients who have had one or more prior laryngeal attacks, patients who have had between 1 and 2, 2 and 3, or more than 3 HAE attacks in the four weeks prior to the first dose of the first treatment period; and/or has received treatment with a C1-inhibitor prior to the first treatment period.
    Type: Application
    Filed: May 16, 2022
    Publication date: April 6, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Peng Lu, Christina Nurse, Xinming Hao
  • Syringe screening device
    Patent number: 11614381
    Abstract: The present disclosure is directed to a device for screening pre-filled syringes configured to determine whether a stopper position within each syringe falls within an acceptable tolerance prior to final assembly of a syringe into a corresponding autoinjector device, thereby ensuring proper fit of the syringe within the autoinjector device and further ensuring accurate delivery of a desired dose of fluid from the syringe during operation of the autoinjector.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: March 28, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Chase Fetzer, Evi Shiakolas
  • Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
    Patent number: 11613586
    Abstract: The present disclosure relates to anti-CD38 antibodies and their use as therapeutics and diagnostics. The present disclosure further relates to methods of treating autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis. The present disclosure further relates to diagnostic assay methods for identifying patients having autoimmune diseases for treatment.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: March 28, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Glennda Smithson, Jose Estevam, Nicholas Jones
  • T-cell receptor
    Patent number: 11603519
    Abstract: Provided is a T cell receptor capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 27 or a complex of the peptide and HLA-A24. A T cell receptor capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 28 or a complex of the peptide and HLA-A02. Disclosed T cell receptors are useful in treating or avoiding cancers which are associated with expression of glypican-3.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: March 14, 2023
    Assignees: National Cancer Center Japan, Kyoto University, Takeda Pharmaceutical Company Limited
    Inventors: Tetsuya Nakatsura, Toshiaki Yoshikawa, Yasushi Uemura, Kyoko Fukuda, Shin Kaneko, Atsutaka Minagawa, Yoshiaki Kassai, Atsushi Matsuda
  • Libraries of genetic packages comprising novel HC CDR1, CDR2, and CDR3 and novel LC CDR1, CDR2, and CDR3 designs
    Patent number: 11598024
    Abstract: Provided are compositions and methods for preparing and identifying antibodies having CDR3s that vary in sequence and in length from very short to very long which in certain embodiments may bind to a carbohydrate moiety or the active site of an enzyme. Libraries coding for antibodies with the CDR3s are also provided. The libraries can be provided by modifying a pre-existing nucleic acid library.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: March 7, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventor: Robert Charles Ladner